Back to Search Start Over

Clinical significance of circulating tumor cells in colorectal cancer with peritoneal metastases: a prospective cohort study using a novel method for monitoring treatment response, and assessing minimal residual disease.

Authors :
Frühling P
Moberg L
Ghanipour L
Birgisson H
Graf W
Ericsson C
Cashin PH
Source :
International journal of surgery (London, England) [Int J Surg] 2024 Jul 08. Date of Electronic Publication: 2024 Jul 08.
Publication Year :
2024
Publisher :
Ahead of Print

Abstract

Background: The treatment for patients with colorectal cancer with metastases to the peritoneum is complex and may involve both surgery and chemotherapy. Circulating tumor cells (CTCs) have been poorly investigated in peritoneal metastatic colorectal cancer. The aim of the study is to examine the role of circulating tumor cells (CTCs) as a biomarker for monitoring disease progression, treatment response and residual disease using CellMate® - a new promising in vitro diagnostic platform technology.<br />Materials and Methods: We prospectively followed clinical outcomes of 46 patients treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal cancer with peritoneal metastases and examined whether CTCs were present the week of surgery. The CTC measurements were made with the CellMate® technology, which is a platform technology to detect CTCs based on the difference in biomechanical properties compared to blood resident cells. The study was registered online (ClinicalTrials.gov).<br />Results: CTCs were detected in 17 (37%) patients. The presence of CTCs was associated with shorter recurrence-free survival and overall survival after CRS and HIPEC. Both recurrence free survival (HR 4.00, 95%CI 1.15-13.9; P=0.029) and overall survival (HR 5.91; 95% CI 1.18-29.7; P=0.03) were significantly worse if CTCs were detected after neoadjuvant treatment. In the subgroup of patients with CTCs detected, adjuvant therapy tended to improve the prognosis while in CTC negative patients it did not.<br />Conclusions: Pending a prospective multi-center trial to validate these findings, CTCs may in the future be used as a dynamic personalized biomarker for prognostication, predicting response to therapy, and for monitoring disease progression in colorectal cancer with metastases to the peritoneum.<br /> (Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.)

Details

Language :
English
ISSN :
1743-9159
Database :
MEDLINE
Journal :
International journal of surgery (London, England)
Publication Type :
Academic Journal
Accession number :
38978470
Full Text :
https://doi.org/10.1097/JS9.0000000000001906